- Home
- RPAY vs AURA Comparison
RPAY vs AURA Comparison
Compare RPAY & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- AURA
- Stock Information
- Founded
- RPAY 2006
- AURA 2007
- Country
- RPAY United States
- AURA United States
- Employees
- RPAY N/A
- AURA N/A
- Industry
- RPAY Business Services
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- RPAY Consumer Discretionary
- AURA Health Care
- Exchange
- RPAY Nasdaq
- AURA Nasdaq
- Market Cap
- RPAY 387.2M
- AURA 396.8M
- IPO Year
- RPAY N/A
- AURA 2021
- Fundamental
- Price
- RPAY $4.79
- AURA $6.49
- Analyst Decision
- RPAY Buy
- AURA Strong Buy
- Analyst Count
- RPAY 9
- AURA 6
- Target Price
- RPAY $8.06
- AURA $22.33
- AVG Volume (30 Days)
- RPAY 1.3M
- AURA 217.8K
- Earning Date
- RPAY 08-07-2025
- AURA 08-07-2025
- Dividend Yield
- RPAY N/A
- AURA N/A
- EPS Growth
- RPAY N/A
- AURA N/A
- EPS
- RPAY N/A
- AURA N/A
- Revenue
- RPAY $309,647,000.00
- AURA N/A
- Revenue This Year
- RPAY N/A
- AURA N/A
- Revenue Next Year
- RPAY $8.40
- AURA N/A
- P/E Ratio
- RPAY N/A
- AURA N/A
- Revenue Growth
- RPAY 2.26
- AURA N/A
- 52 Week Low
- RPAY $3.59
- AURA $4.35
- 52 Week High
- RPAY $10.16
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- RPAY 48.67
- AURA 59.68
- Support Level
- RPAY $4.84
- AURA $5.96
- Resistance Level
- RPAY $5.12
- AURA $6.68
- Average True Range (ATR)
- RPAY 0.16
- AURA 0.36
- MACD
- RPAY -0.00
- AURA 0.01
- Stochastic Oscillator
- RPAY 42.61
- AURA 97.70
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.